|
🐢
|
Maraviroc for previously treated patients with R5 HIV-1 infection.
18 auth.
R. Gulick,
J. Lalezari,
J. Goodrich,
N. Clumeck,
E. Dejesus,
A. Horban,
J. Nadler,
B. Clotet,
A. Karlsson,
M. Wohlfeiler,
...
J. B. Montana,
Mary Mchale,
J. Sullivan,
C. Ridgway,
S. Felstead,
M. Dunne,
E. van der Ryst,
H. Mayer
|
9 |
2008 |
9
🐢
|
|
🐜
|
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
21 auth.
G. Fätkenheuer,
M. Nelson,
A. Lazzarin,
I. Konourina,
A. Hoepelman,
H. Lampiris,
B. Hirschel,
P. Tebas,
F. Raffi,
B. Trottier,
...
Nicholaos C. Bellos,
M. Saag,
D. Cooper,
M. Westby,
M. Tawadrous,
J. Sullivan,
C. Ridgway,
M. Dunne,
S. Felstead,
H. Mayer,
E. van der Ryst
|
8 |
2008 |
8
🐜
|
|
🐜
|
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
11 auth.
Z. Brumme,
J. Goodrich,
H. Mayer,
C. Brumme,
B. Henrick,
B. Wynhoven,
...
J. Asselin,
Peter K. Cheung,
Robert S. Hogg,
J. Montaner,
P. R. Harrigan
|
8 |
2005 |
8
🐜
|
|
🐢
|
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
21 auth.
D. Cooper,
J. Heera,
J. Goodrich,
M. Tawadrous,
M. Saag,
E. Dejesus,
N. Clumeck,
S. Walmsley,
Naitee Ting,
E. Coakley,
...
J. Reeves,
G. Reyes-Terán,
M. Westby,
E. van der Ryst,
P. Ive,
L. Mohapi,
H. Mingrone,
A. Horban,
F. Hackman,
J. Sullivan,
H. Mayer
|
8 |
2010 |
8
🐢
|
|
🐜
|
Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.
7 auth.
G. Moyle,
A. Wildfire,
S. Mandalia,
H. Mayer,
J. Goodrich,
J. Whitcomb,
...
B. Gazzard
|
7 |
2005 |
7
🐜
|
|
🐬
|
Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections
P. Ambrose,
D. Grasela,
T. Grasela,
J. Passarell,
H. Mayer,
P. Pierce
|
7 |
2001 |
7
🐬
|
|
🐢
|
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
9 auth.
M. Saag,
J. Goodrich,
G. Fätkenheuer,
B. Clotet,
N. Clumeck,
J. Sullivan,
...
M. Westby,
E. van der Ryst,
H. Mayer
|
7 |
2009 |
7
🐢
|
|
🐬
|
Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections
P. Ambrose,
D. Grasela,
T. Grasela,
J. Passarell,
H. Mayer,
P. Pierce
|
6 |
2001 |
6
🐬
|
|
🐢
|
A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease
13 auth.
W. Reinisch,
J. Panés,
M. Lémann,
S. Schreiber,
B. Feagan,
S. Schmidt,
G. Sturniolo,
T. Mikhailova,
O. Alexeeva,
L. Sanna,
...
T. Haas,
S. Korom,
H. Mayer
|
6 |
2008 |
6
🐢
|
|
🐜
|
Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2
8 auth.
W. Hardy,
R. Gulick,
H. Mayer,
G. Fätkenheuer,
M. Nelson,
J. Heera,
...
N. Rajicic,
J. Goodrich
|
6 |
2010 |
6
🐜
|
|
🐜
|
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients
9 auth.
N. Funderburg,
M. Kalinowska,
James Eason,
J. Goodrich,
J. Heera,
H. Mayer,
...
N. Rajicic,
H. Valdez,
M. Lederman
|
6 |
2010 |
6
🐜
|
